1. Academic Validation
  2. Succimer chelation normalizes reactivity to reward omission and errors in lead-exposed rats

Succimer chelation normalizes reactivity to reward omission and errors in lead-exposed rats

  • Neurotoxicol Teratol. 2007 Mar-Apr;29(2):188-202. doi: 10.1016/j.ntt.2006.11.004.
Stéphane A Beaudin 1 Diane E Stangle Donald R Smith David A Levitsky Barbara J Strupp
Affiliations

Affiliation

  • 1 Division of Nutritional Sciences, Cornell University, Savage Hall, Ithaca, NY 14853, USA.
Abstract

This study evaluated the efficacy of a 3-week course of succimer treatment to alleviate behavioral deficits in rats exposed to lead (Pb) for the first 4 weeks of life. A 3 x 2 factorial design was used: three levels of lead exposure (No Pb, Moderate, and High Pb) and two levels of chelation (succimer or vehicle). Behavioral testing was conducted following chelation therapy, from 2 to 9 months of age; this report presents the results of two of the administered tasks: (1) a conditional olfactory discrimination task (baseline task), and (2) a conditional olfactory discrimination task with periodic reward omission on some correct trials (RO task). In the RO task, the performance disruption produced by committing an error on the previous trial was significantly greater for both unchelated lead-exposed groups than for controls. The High Pb rats were also more sensitive to reward omission than controls, providing converging evidence for impaired regulation of arousal or emotion. Importantly, succimer treatment was effective in normalizing the heightened reactivity of the lead-exposed Animals to both errors and reward omission. In addition, non-lead-exposed rats that were treated with succimer tended to be more affected by a prior error than controls in their latency to respond on post-error trials. In sum, these findings provide new evidence that succimer chelation can significantly lessen the lasting neurobehavioral dysfunction produced by early lead exposure, but also suggest that there may be risks of administering the drug to individuals without elevated blood lead levels.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-B1768
    ≥98.0%, Chelating Agent